Floatz logo

.Alpha.-1 Protease Inhibitor

Chronic Obstructive Pulmonary Disease

Takedaprotein_peptidePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Chronic Obstructive Pulmonary Disease cohort.

Asset / SponsorPhaseRating
Liraglutide
Claus Bogh Juhl
Phase 4BB
Roflumilast
Prince of Songkla University
Phase 3BB
Ciprofloxacin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
20-valent pneumococcal conjugate vaccine
University of Alabama at Birmingham
Phase 4BB
Tazobactam
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB

View all 50 →

Same molecule, other indications

.Alpha.-1 Protease Inhibitor is also rated in:

alpha 1-antitrypsin deficiencyActive
A
Indicative · Phase 4
81 / 100
View asset →
pulmonary emphysemaActive
B
Indicative · Phase 2
62 / 100
View asset →
type 1 diabetes mellitusDormant
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →